Here, we report that in addition to baseline defects in the enforcement of immune tolerance, Treg‐specific TRAF6 deficiency leads to impaired Treg function in vivo, heightened anti‐tumor immunity, and resistance to implanted tumors. This evidence concerns the gene TRAF6 and neoplasm.